Algeta, a Norwegian company focused on the development of novel targeted cancer therapeutics, has appointed Andreas Menrad as Chief Scientific Officer and a member of the executive management team.
In this newly created role, Menrad takes responsibility for developing and executing the company’s research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a growing and experienced R&D team.
Menrad brings more than 20 years of experience in the pharmaceutical and biotech industry, with a strong background in oncology therapeutic development. He joins Algeta from Ablynx, where he was CSO.
Prior to this, Menrad spent five years at Genzyme (Sanofi) in Cambridge, UK, where most recently he held the role of General Manager and Vice President of Antibody Therapeutics. Before that, he spent 15 years at Schering in senior research roles focused on oncology and antibody engineering.
Algeta has also announced that Thomas Ramdahl, Executive Vice President, will take up the position of Chief Operating Officer, with responsibilities for key aspects of the company’s European operations, its global manufacturing assets and its intellectual property portfolio.